Related Experiment Videos
Immunosuppressive agents for treating IgA nephropathy.
J A Samuels1, G F M Strippoli, J C Craig
1Nephrology / Pediatric Nephrology, UT-Houston Health Science Center, 6431 Fannin Street, MSB 4-148, Houston, TX 77030, USA. Joshua.A.Samuels@uth.tmc.edu
The Cochrane Database of Systematic Reviews
|October 30, 2003
Summary
Immunosuppressive treatments, particularly steroids, show promise in slowing IgA nephropathy (IgAN) progression and reducing protein in urine. However, optimal management and patient selection require further research due to study limitations.
Area of Science:
- Nephrology
- Immunology
- Clinical Trials
Background:
- IgA nephropathy (IgAN) is a significant global cause of end-stage renal failure (ESRF).
- Established treatments for IgAN are lacking, prompting investigation into various therapeutic approaches.
Purpose of the Study:
- To evaluate the efficacy and safety of immunosuppressive therapies for IgA nephropathy.
- To synthesize evidence from randomized controlled trials (RCTs) on immunosuppressive treatments for IgAN.
Main Methods:
- Systematic review and meta-analysis of RCTs and quasi-RCTs.
- Searched multiple databases including Cochrane, MEDLINE, and EMBASE up to September 2002.
- Data extraction and quality assessment performed independently by two reviewers.
Main Results:
- Thirteen RCTs with 623 patients were analyzed.
- Steroid treatment reduced the risk of progression to ESRF and urinary protein excretion.
- Alkylating agents/cyclosporin also decreased urinary protein excretion compared to placebo.
Conclusions:
- Immunosuppressive interventions, especially steroids, appear beneficial for IgAN.
- Optimal management and patient subgroups that benefit most require further investigation.
- High-quality RCTs are needed to clarify treatment benefits and harms.